GW-Led Research uses SeqLL’s tSMS® platform to identify novel signature for detection of coronary artery disease WOBURN, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel […]